Posts Tagged ‘hormone replacement’

Can the Risk of Colorectal Cancer Among Obese People be Reduced?

Friday, January 22nd, 2016

logo1267406_mdA new study published in Cancer Research concluded that they have discovered the biological previously unfound connection of a long known association between obesity and an increased risk of colorectal cancer. They have also identified an approved drug that might prevent  the cancer in obese people.

In research they found that a high caloric diet turned off expression of a key hormone in the intestines, which lead to deactivation of a tumor suppressor pathway. Genetic replacement of that hormone turned the tumor suppressor back on and prevented cancer development even when mice continued to eat excess calories. The drug that was used was linaclotide (Linzess) that is structurally related to the hormone and may be a therapeutic approach to prevent colorectal cancer in obese patients. The researchers said “Our study suggests that colorectal cancer can be prevented in obese individuals with the use of hormone replacement therapy.”

In the study they used genetically engineered mice on different diets and found that obesity (either from excess fat or carbohydrate consumption. or both, is associated with loss of the hormone guanylin, that is produced in the intestine’s epithelium or cells lining the intestines. The hormones turn on its receptor guarylyl  cyclase (GUCY2C) that regulates processes underlying regeneration of the intestinal epithelium. “The lining of the intestines is very dynamic and continuously being replaced, and the GUCY2C contributes to the choreography of the key processes  needed for thus regeneration.”  Deactivation of the guanylin gene is common in colorectal cancers in both humans and animals and morbidly ovese patients echibit an 80% decrease in Guanylin gene expression compared to lean people.

In this study they found the consequence of that loss is that , and without the hormone, the receptor is silent. the guanylin  hormone receptor acts as a growth-controlling tumor suppressor happening early in the cancer development. “When the receptor is silenced, the epithelium becomes dysfunctional, setting up the conditions for cancer development.” The research demonstrates that obese mice, compared to lean mice, were much more likely to silence the hormone and its receptor, “We believe that if colorectal cancer is going to develop, it will be through this silencing mechanism-and that it will happen much more frequently in the obese.” This study demonstrates that if you can prevent hormone loss, you can also prevent tumor development and  a drug like guanylin, can activate GUCY2C tumor-suppressing receptors to prevent cancer in these patients.

Researchers have already started multi site clinical studies testing dose and side effects of linaclotide use in healthy volunteers.


Guests for Next Week Include Dr David Rosensweet (Menopause and Hormone Replacement) and Diane Collins (Quantum Thinking).

Sunday, October 19th, 2014

Dr. Rosensweet Picture

Dr. David Rosensweet graduated from the University of Michigan Medical School in 1968.  He has been in private medical practice since 1971, has had offices in New Mexico, California, and Colorado and is currently in practice in Southwest Florida.  Formerly the clinical physician involved in the very first Nurse Practitioner training program in the U.S.A. and in charge of health promotion for the State of New Mexico.  He teaches health professionals about the treatment of women in menopause with bioidentical hormones. Some highlites of his career follow:

  • Nationally known lecturer and frequent presenter at A4M and ACAM
  • Principle Investigator for a scientific study of female hormones sponsored by Metametrix Clinic Laboratory
  • Author of the book The Target Method – A Woman’s Guide to Navigating Menopause
  • Organizer of a National Summit Committee on the Treatment of Women in Menopause with Bio-identical Hormones
  • Formerly on the Board of Directors of the American College of Advancement in Medicine, and the Chairman of its Endocrine Committee              More information is available at:

D collins

Dianne Collins is an original thinker, media personality, and one of the foremost thought-leaders of our time. She is a master of translating ancient knowledge into “quantum” modern wisdom that provides a transformative platform for the way we conduct our business and personal affairs. Dianne is the creator and author of QuantumThink, a new system of thinking that has us leap from the outdated “old world view” limits of the Industrial Age to begin thinking from the more accurate and up-to-date “new world view” of our current Quantum Age. Along with her husband and business partner, she consults visionary leaders and executives in the world’s leading corporations including Accenture, AT&T, CNN and Dupont as well as presenting QuantumThink to entrepreneurs and students, homemakers and professionals, celebrities and evolutionaries worldwide.  More information is available at:


Another Study Finds Increased Breast Cancer Risk from Hormone Therapy

Friday, August 20th, 2010


A new study published in Cancer Epidemiology, Biomarkers & Prevention concluded that the risk of breast cancer varies by personal characteristics but this study reinforced that there is an increased risk of breast cancer from hormone use and further studies are needed to address how specific that risk is. Hormone replacement therapy among 2,857 women were analyzed for almost 10 years and it was found that when compared with women who never used hormone therapy, women who used estrogen therapy for more than 15 years had a 19 percent greater risk of developing breast cancer. For those who used a combined program of estrogen and progestin for 15 or more years the risk increased 83 percent. Thus, the breast cancer risk was highest for the combined hormone therapy group.
Results also showed that breast cancer risk was dependent on body mass index (BMI) because those with a BMI under 30 seemed to have an increased risk with combined therapy and it was highest for women with a BMI under 25. On the other hand obese women with a BMI over 30 had no further risk associated with using combined hormone therapy. The risk for these breast tumors were for tumors that were positive for both estrogen and progestin receptors and were weaker for HER2 negative tumors. Further research is need to answer lingering questions for this complex association.

However, in another study published in the September issue of Cancer Prevention Research researchers found that breast cancer risk varies by the type of progestin used in hormone therapy. In the study they compared the effect of 4 progestins on breast cancer in animal models. Progestins used included 1) synthetic progestin medroxporgresterone acetate (MPA), 2) norgesterel (N-EL), 3) norethindrone (N-ONE) and 4) megestrol acetate (MGA). The MPA progestin in Prempro is most often used by women in the United States for Hormone Therapy. The authors concluded “although previous studies using an animal model for breast cancer found the MPA functions as a tumor promoter, this study showed that N-EL and N-ONE……. strongly inhibited tumor development.” Progestins seems to have tumor stage specific effects that determines whether they function as tumor promoters or protectors. Those such as N-EL and N-ONE seem to prevent breast cancer in women without a history of or family history for breast cancer and for post menopausal women who are at increased risk due to combined estrogen/progestin (MPA) hormone therapy.